Targeting CTLA‐4 in cancer: Is it the ideal companion for PD‐1 blockade immunotherapy combinations?

Immunotherapy approaches boosting spontaneous and durable antitumor immune responses through immune checkpoint blockade are revolutionizing treatment and patient outcomes in solid tumors and hematological malignancies. Among the various inhibitory molecules employed by the immune system to regulate the adaptive immune responses, cytotoxic T lymphocyte antigen‐4 (CTLA‐4) is the first successfully targeted immune checkpoint molecule in the clinic,...